Skip to main content
. 2015 Aug 28;21(32):9588–9597. doi: 10.3748/wjg.v21.i32.9588

Figure 1.

Figure 1

Antiviral agent utilization before and after reimbursement for patients with different characteristics. A: Antiviral agent utilization before and after reimbursement for patients with different insurance types; B: Utilization of different NAs for PMI vs PPO before and after reimbursement C1: Utilization of specific antiviral among new and existing PMI before reimbursement; C2: Utilization of specific antiviral among new and existing PMI after reimbursement; C3: Utilization of specific antiviral among new and existing PPO before reimbursement; C4: Utilization of specific antiviral among new and existing PPO after reimbursement. aP < 0.05, bP < 0.01, before reimbursement vs after reimbursement. PMI: Patients with medical insurance; PPO: Patients paid out-of-pocket.